Human Genome (HGSI) volatility low at 73 after announcing positive data
Down)
Human Genome (Nasdaq: HGSI) is recently down $1 to $24.28 in pre-open trading. HGSI rallied on November 2 after announcing its Benlysta met the goal of a second late-stage study treating lupus. ThinkEquity has a Buy rating on HGSI. HGSI November option implied volatility is at 73, below a level of 240 from last week according to Track Data, suggesting decreasing movement. Paul Foster
You May Also Be Interested In
- Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI) (COG) Downgraded
- Vodafone (VOD) Volatility Pops Early, Shares Inch Higher
- Stocks with Implied Volatility Movement; PCX JOY
Create E-mail Alert Related Categories
OptionsRelated Entities
ThinkEquitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
